KPIs & Operating Metrics(New)
Growth Metrics

Bristol Myers Squibb (BMY) Payables (2016 - 2026)

Bristol Myers Squibb has reported Payables over the past 18 years, most recently at $4.2 billion for Q1 2026.

  • Quarterly Payables rose 5.8% to $4.2 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $4.2 billion through Mar 2026, up 5.8% year-over-year, with the annual reading at $3.6 billion for FY2025, 0.75% down from the prior year.
  • Payables was $4.2 billion for Q1 2026 at Bristol Myers Squibb, up from $3.6 billion in the prior quarter.
  • Over five years, Payables peaked at $5.4 billion in Q2 2025 and troughed at $2.6 billion in Q3 2022.
  • The 5-year median for Payables is $3.5 billion (2024), against an average of $3.5 billion.
  • Year-over-year, Payables dropped 20.14% in 2022 and then skyrocketed 44.68% in 2025.
  • A 5-year view of Payables shows it stood at $3.0 billion in 2022, then grew by 7.2% to $3.3 billion in 2023, then rose by 10.52% to $3.6 billion in 2024, then decreased by 0.75% to $3.6 billion in 2025, then increased by 18.43% to $4.2 billion in 2026.
  • Per Business Quant, the three most recent readings for BMY's Payables are $4.2 billion (Q1 2026), $3.6 billion (Q4 2025), and $4.3 billion (Q3 2025).